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Treatment Policies
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Abstract
Increased clinical interest in individualized ‘adaptive’ treatment policies has shifted
the methodological focus for their development from the analysis of naturalisti-
cally observed strategies to experimental evaluation of a pre-selected set of strate-
gies via multi-stage designs. Because multi-stage studies often avoid the ‘curse of
dimensionality’ inherent in uncontrolled studies, and hence the need to paramet-
rically smooth trial data, it is not surprising in this context to find direct connec-
tions among different methodological approaches. We show by asymptotic and
algebraic proof that the maximum likelihood (ML) and optimal semi-parametric
estimators of the mean of a treatment policy and its standard error are equal under
certain experimental conditions. The two methodologies offer conceptually dif-
ferent formulations, which we exploit to develop a unified and efficient approach
to design and inference for multi-stage trials of policies that adapt treatment ac-
cording to discrete responses. We derive a sample size formula expressed in terms
of a parametric (regression-based) version of the optimal semi-parametric popula-
tion variance. Non-parametric (sample-based) ML estimation performed well in
simulation studies, in terms of achieved power, even though sample sizes relied
on parametric re-expression. For a variety of simulated scenarios, ML outper-
formed the semi-parametric approach, which used a priori rather than estimated
randomization probabilities, because the test statistic was sensitive to even small
differences arising in finite samples.
 
 
1.  Introduction 
 
Increased clinical interest in individualized treatment policies has shifted the 
methodological focus for their development from the analysis of ‘naturalistically’ 
observed strategies (Murphy et al. 2001; Hernan et al. 2006) to experimental 
evaluation of a pre-selected set of strategies via multi-stage designs (Lavori and 
Dawson, 2000; Thall et al., 2000; Lunceford et al., 2002).  The candidate policies 
under evaluation have been described as ‘adaptive’ treatment strategies (ATS) or 
‘dynamic’ treatment regimes (Lavori and Dawson 2008) because treatment 
changes are tailored to the circumstances of the individual, including response to 
prior treatments.  The studies have been described as sequential, multiple 
assignment, randomized (SMAR) trials (Murphy 2005) because successive 
courses of treatment are randomly and adaptively assigned over time, according 
to the individual subject’s treatment and response history.  The multiple stages of 
randomization correspond to the sequential decision making formalized by an 
ATS, the primary goal of the trial being to evaluate entire strategies, rather than 
stage-specific treatment options.  
 
A typifying example of an adaptive treatment strategy occurs in the 
treatment of a chronic disorder such as depression.  The following ATS 
exemplifies the decision algorithm used in the SMAR trial of antidepressants 
known as STAR*D (Rush et al. 2004):  ‘Start on A; after a sufficient medication 
trial, switch to B if response is poor or side effects persist, otherwise either 
continue on A or augment A with C, depending on the degree of improvement; 
continue to monitor and augment or switch to treatments D and F, respectively, 
according to degree of response.’  As in STAR*D, the SMAR design specifies 
that all subjects in the trial start on A, so that the first randomization is to possible 
treatment options for B and C , which is nested within the response categories for 
treatment with A.  For example, subjects who experience side effects are 
randomized to one of the alternatives for B.  Further randomization to options for 
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D and F is similarly nested within previous treatment and response history.  
Subjects who respond well enough to A and continue to do so are never 
randomized, but participate fully in all stages of the trial.   
 
Clinical equipoise successively guides SMAR treatment options for B,C, D 
and F, just as it guides fixed treatment alternatives in single-stage trials (Dawson 
and Lavori 2010).   That principle, coupled with standardizing of clinical details 
(e.g., dosing, duration of medication trial), reduces the typically explosive 
variation in treatment regimes found in observational settings (Lavori and 
Dawson 2004).  Because SMAR studies often avoid the ‘curse of dimensionality’ 
inherent in uncontrolled studies, and hence the need to parametrically smooth 
trial data, it is not surprising in this context to find direct connections among 
different methodological approaches.  This paper shows that the simplest 
estimators of the population mean of an ATS and its standard error, derived 
using probability calculus and ‘plug-in’ method of moments estimates, are equal 
under certain experimental conditions to the analogous estimators provided by 
optimal semi-parametric theory, maximum likelihood (ML) theory, and Bayesian 
predictive inference.  In particular, we assume that constrained randomization 
(e.g., sequential blocking) insures that the observed allocation of subjects 
matches that intended by design (Dawson and Lavori 2008).  We also assume 
that the specification of the ATS  and the choice of SMAR sample size insure 
‘replete’ datasets at the end of the experiment,  in the sense of precluding 
random zeroes at intermediate randomization steps (Lavori and Dawson 2007). 
 
   The equality of the optimal variance estimator with the others is not 
obvious by appearance and full induction across randomization stages is 
required to derive the result algebraically.  The different formulations for standard 
error clarify how the distinct methodological perspectives complement each 
other.   The iterative probability calculus (also underlying ML and predictive 
estimators) is carried out sequentially according to the nested structure of SMAR 
data, to reflect the influence due to intervening outcomes used for multi-stage 
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randomization.  The resulting variance estimator decomposes into stage-specific 
components corresponding to the uncertainty associated with estimating the 
conditional distributions of successive outcomes.  In this way, it quantifies the 
inference ‘penalty’ paid at each SMAR stage for not knowing a priori the 
population parameters for their joint distribution.  By contrast, the efficient semi-
parametric influence function used to obtain the optimal variance estimator is a 
‘marginal’ mean model for the outcome measured at the end of the study 
(Murphy et al. 2001).  The resulting variance estimator derives from the 
population marginal variance of the final outcome, typically used for determining 
sample size in single-stage trials, plus a sum of stage-specific variances of the 
inversely weighted final outcome. 
 
In this paper, we exploit the marginal character of the semi-parametric 
approach to derive a regression-based formula suitable for sample size 
calculations, which minimizes reliance on unknown population parameters and is 
expressed in quantities familiar to the trialist.  We also derive a non-parametric 
counterpart for the semi-parametric efficiency gains provided by the optimal 
estimator, relative to the simpler marginal mean estimator defined by Murphy for 
SMAR trials (2005).  We consider the performance of ML and semi-parametric 
inference, in terms of achieved power, when using the regression-based sample 
size formula.  The intent is to provide a unified and efficient approach to design 
and inference for SMAR trials of ATS that adapt treatment according to discrete 
responses.   
 
 
2.   Design Framework and Estimators 
 
Consider a SMAR trial with K stages of randomization.  The multi-stage design 
can be described sequentially in terms of the adaptive randomized treatment 
assignments.  Let be the (observed) baseline state of the subject, taking 
values denoted by  and let  be initial treatment assigned as a function of  
1S
,1s 1A ,1s
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taking values denoted by .   Analogously for stage k in 2, … , K let  be the 
status of the subject measured at the start of the kth stage and  the treatment 
assigned by the kth randomization according to values for and , where  
= , ,…, and = , , …, .  SMAR assignment to different 
treatment options can be expressed in terms of (sequential) allocation to different 
decision rules, each of which determines treatment as a function of the current 
and past states and past treatments.  Formally, we write = = = 
 for the decision rule at the kth stage; the randomization probabilities for 
 denoted { , )}, are known and experimentally fixed functions of 
prior state-treatment history.   
1a
(
kd
1-kA
kS
1-
,ks
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The (observable) strategies to be evaluated from the multi-stage design 
can be represented as sequences of the SMAR decision rules with positive 
probability of assignment.  Specifically, each SMAR sequence { , , …, Kd
=1S
} 
corresponds to an ATS, which we denote as d, if the domain for each successive 
rule includes the state-treatment histories produced by previous rules in the 
sequence.  This condition insures that the K-stage ATS is a well-defined policy 
for adaptively determining the ‘next’ treatment.  The introductory example 
consists of two decision rules { , }, given that all subjects in the SMAR trial 
start on A :  A  = d , A+C  =   and B  = d , 
where the baseline state indicates response to A.  The second decision rule is 
similarly defined.  For example,  = ), where  indicates 
response measured after the first randomization.  The more cumbersome 
notation, such as  makes explicit that treatment is a function of prior state-
treatment history.    
1d
1a
2d
a
)2( =11 Sd
,1( =22 S 1a
)1(1
2a
a )1(1
,)1,1(
=1S
1S
)2(1a
)1,1( d
)3(1a
2S
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2
 
 The SMAR design includes a primary outcome Y, obtained after the Kth 
stage of randomization, which is used for evaluation purposes.  We judge the 
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performance of an ATS d by d , the population mean of Y that would be 
observed if all subjects were treated according to d. 
 
 
2.1   Estimator of the Mean of an ATS 
 
Previously, we derived a method of moments estimator of d from SMAR trial 
data using iterated expectation and showed that under certain experimental 
conditions, it is equal to the marginal mean (MM) estimator defined by Murphy for 
SMAR trials (Lavori and Dawson 2007).  Specifically, the two estimators are the 
same when at any given stage k, the proportion of subjects with state-treatment 
history ( ) randomized to d coincides with the assignment probability 
, ).  Such coincidence occurs asymptotically by the law of large 
numbers and might be achieved in a study using sequentially blocked 
randomization.  When this holds, both estimators of 
1-, kk AS
kS 1-kA|( kk dp
d  can be expressed in 
terms of stage-specific, stratified sample quantities as: 
 
∑ )()(
K
KKKK m
s
ss                                                                                      (1) 
                        
where is the sample mean of final responses among subjects 
sequentially randomized to d through K and having state values = , 
)( KKm s
KS Ks
                
 )( KK s = ∏                                                                 (2) 
1=
)(
K
k
kkf s
                         
and  is the sample (conditional) response rate for = , given 
assignment to d through k-1 and = .  The estimator (1) is a version of the 
non-parametric G-computational formula (Robins 1989) and is suitable for 
strategies that adapt treatment according to discrete states, such as the ATS in 
)( kkf s kS ks
1-kS 1-ks
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the Introduction.  Under the assumption of sequential ignorability (guaranteed by 
multi-stage randomization), (1) is consistent for d .   
 
Murphy et al. (2001) derived a semi-parametric estimator of d , deemed 
optimal because it has the smallest variance among the class of all regular 
asymptotically linear (RAL) estimators.  Let  
 
kD d
)(P s
= ∏ = , ))  
1=
(
k
j
jAI jj S( 1-jA
 
indicate assignment to strategy d through stage k, where is 1 if B occurs, 
otherwise 0, and let 
)(BI
                        
  =  kk ∏
1=
1- ),|(
k
j
jjjj dp AS
 
be the probability of being sequentially randomized through k to d given = . 
The optimal estimator is obtained by solving the efficient estimating equation  
kS ks
∑1 optn U = 0, where n is the number of subjects and  is defined as: optU
          
 ),,,( dKKKoptU μdS  = )}){ 1-1- ( KKKKK ,K ds
+1( ks
μ-YPD (s                                 (3) 
 
              +   ∑1
1=
1-1+ )},(-),){(1-
-K
k
kkkkkkkk PD dd ss 
 
                                           +  )({ 11 s - }d  
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with ),( 1-kkk ds = for k in 1,...,K;  denotes the primary 
outcome when the subject is treated according to strategy d.  Note that for k = 1, 
)=,=|( 1-1- kkkkYE dAsSd dY
), 1-kk ds(k  )1s(1 .  
 
 The G-computational formula (1) can be used to provide consistent non-
parametric estimates of the k (given SMAR randomization), in which case, the 
solution to the estimated estimating equation is optimal (Murphy et al. 2001).  It 
also reduces to (1).  This follows because all but the last term of  are zero 
when the G-estimates for 
optU
k are ‘plugged’ into (3); solving the last term of the 
estimating equation (using the plug-in G-estimate) leads to (1).  The result holds 
asymptotically without restriction, but otherwise requires that the observed 
allocation of subjects matches that intended by design, as noted above for the 
MM estimator.  This condition is required because  uses assignment 
probabilities for inverse weighting, whereas sample estimates in (1) use the 
observed assignment proportions.  Unless stated otherwise, we assume blocking 
or some other form of constrained randomization makes this distinction moot for 
analytic derivations, and use the notation , ) interchangeably for 
expected and observed proportions under strategy d, as well as  for their 
cumulative products. 
optU
k -kA|( kk dp S 1
)kk(P s
 
 Because the ML estimates for means and proportions coincide with the 
‘plug-in’ estimates obtained by the method of moments, (1) is also ML.  It is also 
equal to the predictive estimator of d , assuming non-informative priors 
(Dawson and Lavori 2008).  We therefore refer to (1) unambiguously as the 
estimator of the ATS mean, denoted dˆ . 
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2.2   Variance Estimators of the Estimator of the Mean of an ATS 
 
To obtain the asymptotic ML variance of dˆ , we assume (i) the final outcome Y 
has a stratified normal distribution across strata indexed by the possible 
sequences ( ), (ii) the intermediate states  are distributed conditionally, 
given ( ), as multinomial random variables, (iii) model parameters are 
distinct across state-treatment histories for a given stage k and across stages.  
Because the sequence of nested randomizations in a SMAR trial gives rise to a 
monotone pattern of missingness for each ATS, the likelihood can be factored 
into distinct components, each of which is a complete-data problem.  Standard 
theory dictates that the (asymptotic) ML variance, obtained from the information 
matrix, is block diagonal, with each block corresponding to a complete-data 
component.  It is possible to derive the ML variance from the information matrix 
for the parameters in the factored form of the likelihood, inverting, and then 
transforming back to the original (joint) parameterization.  However, a more 
tractable derivation calculates the ML variance directly using iterated variance 
decomposition (Little and Rubin 1987).   For the SMAR set up, the iterated 
calculation mimics that used to sequentially identify 
KK as , kS
kk as ,
d , and produces the same 
variance estimator previously obtained using probability calculus coupled with the 
method of moments (Lavori and Dawson 2007) or Bayesian predictive inference 
(Dawson and Lavori 2008).  We use  MLv  to denote the variance estimator ofˆ dˆ  
provided by these three derivations.   
 
The expression for MLvˆ  established using iterated decomposition has two 
primary components:  the ‘naïve’ variance estimate that assumes the coefficients 
of  in (1) are known a priori, denoted , and the ‘penalty’ paid for 
estimating them via (2), denoted :    
)( KKm s nvˆ
pvˆ
 
MLvˆ  =  +                   nvˆ pvˆ
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 where (suppressing dependence on state history) 
 
nvˆ =  ;            = ;                              (4)    )(vˆ∑ 2 KK m
Ks
 pvˆ ),(′ ′voˆc∑′, KKKKKK mm ss
                                                                                                                                                             
and )(vˆ Km   is the sample variance of and ))((vˆ KKm s )( KKm s K′  )( ′KK s  
(Dawson and Lavori 2008).  The estimated covariances ), ′(voˆc KK   can be 
obtained by induction on k, with the cross-sectional case K =1 being the usual 
multinomial calculation (Lavori and Dawson 2007).  For general K, there is a 
component of ‘penalty’ variance for each stage due to estimating the conditional 
distributions of  indexed by state history.  The kth-stage term of kS )′,(voˆc KK   
fixed at  can be directly expressed in terms of the large sample variance and 
covariances of the estimated proportions   defined for (2); 
see the Appendix.    
1-ks
),ks ( kkf s( ,1-kkf s )′k,1- s
  
The estimated asymptotic variance of the optimal semi-parametric 
estimator of d , denoted , is obtained non-parametrically from the variance 
of  ( Murphy 2005).  Specifically,  is the estimate of 
OPTvˆ
optU OPTvˆ )(Un optV
1
, where 
                                                
          = )(V optU 2)( dd  -Y  +                                 (5) ∑
1=
2])-(-[( 1-)1
K
k
kkk YPp d
    
and the expectation is calculated under the distribution of ()dE KS  and Y when all 
treatments are assigned according to the strategy d.  As before, the k are 
estimated using the G-computational formula, which guarantees that  
achieves the semi-parametric efficiency bound (Murphy et al. 2001).  
OPTvˆ
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To show equality of the asymptotic ML and optimal semi-parametric 
variance estimators, we posit that Y takes on only a finite number of possible 
values, and reframe the normal model (i) as multinomial.  Given sufficiently large 
n, either specification will give nearly the same sample estimates of mean and 
variance required for ML estimation (Rubin 1987).  Hence, the assumed 
likelihood model for d  can be taken as non-parametric for practical problems, 
such as those arising in the type of SMAR trials considered here.  We also note 
that the semi-parametric efficiency bound for d , which is equal to , is the 
same whether or not the randomization probabilities (the ‘nuisance’ parameters) 
are known (Bickel et al. 1993).  Therefore, for our purposes, it suffices to 
consider the semi-parametric model corresponding to the ‘true’ non-parametric 
model for
OPTvˆ
d , and fixed at the parameter values for the randomization 
probabilities (Robins and Ritov 1997).  Standard theory implies that the semi-
parametric bound is at least as large as the asymptotic ML variance of dˆ , so 
that MLvˆ  .  Moreover, because the optimal estimator of OPTvˆ d is assumed 
equal to the ML estimator of d , given large samples or constrained 
randomization, it follows directly that the asymptotic semi-parametric efficiency 
bound for d  is equal to the Cramer Rao bound for d  or equivalently ML
vˆ
vˆ  
(Tsiatis 2006), thereby establishing equality.  An immediate consequence of this 
result is that the simulation studies previously carried out for ML estimators 
(actually their method of moments and predictive counterparts) pertain to .  
Those studies demonstrate that the estimators have good finite sample coverage 
for the SMAR trials considered here (Lavori and Dawson 2007; Dawson and 
Lavori 2008).   
OPT
 
It is also possible to use induction to algebraically show equality of the 
variance estimators (see the Appendix).  The result demonstrates that the 
normality of the likelihood has no impact on the above proof that MLvˆ = .  A 
key element of the inductive proof is the ANOVA decomposition:  
OPTvˆ
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   ˆ =   + OPTv nvˆ { 2)(
1 ˆ∑  -m  + }])-(-[(
1=
2
k
kKkk mPped∑1- ˆ)1ˆ 1-K dn KK
Ks
               (6) 
                                                                
where   is the sample estimator of()ˆde  ()d obtained via inverse weighting:  
 =                                                                          (7)  
.  
pression of the  in (6) in terms of covariances provides a direct 
                                         
))((ˆ Yhed ∑ )(1- iiKiK, YhPD ,n
1=i
 (As before, we suppress extra notation whenever possible.)   Algebraic re-
ex  2)-( ˆkKm 
comparison of OPTvˆ - nvˆ  to the ‘penalty’ component of MLvˆ , defined in (4).  A
shown in the Appe th-stage covariances derived from OPTvˆ - nvˆ  are 
standard (K = 1) large sample multinomial covariances the ‘pseudo’ 
proportions p= ∏K f  and p′ = ∏ ′K f .  As described abov e -stag
s 
e 
term of  and
difference 
ndix, the k
=kj j
 restricts covari
 of 
kf ′
=kj j
tainty to
e, th
.  Accordingly, the 
 kth
 pvˆ ance uncer kf
MLvˆ - vˆOPT  gives rise to K remainder terms.   An inductive argument 
tim s b
.   Optimal Semi-parametric Variance for Sample Size Calculations 
r
establishes overall equality of the variance es ator y showing that the 
successive remainders telescope to zero. 
 
 
3
 
 dFor the purposes of developing sample size formulae for inference fo ,  we 
an choose either formulation of the variance estimator for c dˆ .  Here, we exploit 
 Vthe marginal character of the semi-parametric approach and re-express (Uopt
in terms of regression quantities that would be familiar to the trialist.  To do so, 
)  
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we assume that ]|)-[( ,2 kkY dd s  = )|( ,kYV dd s  = ),2 kk ( ds is homogeneo
across state history at k, i.e., ),2 kk( ds   2,dk  .2k   Applying iterated expectation
to the stage k term
 
 ])-(-1[( 21-) kkk YPp d  =  
us 
 
                    (8a) 
                            
                                       
robabilities  is re-expressed as: 
 2 +                                       (9)
 in (5) yields: 
d
                   
              d
- p
 all equal to ).( kk dp
1
21-)-1( kkk Pp             
]],kds|)-( 2kY 
                
)(UoptV
                     
-1[( ) kk Ppd
]-1 1-) kk Pp 
1-) kP  if the k
  In this case, 
                      
[
[(
k
   
1-
2
k
th
 
  
  =                      (8b) 
 
Furthermore, ]-1[( 1-) kk Ppd =  1( -stage randomization 
p are
                       
K
Y  ∑
=
 
k
                                
here
 
w   inal variance of dY .  Let 22Y  is the marg 2,dY  )221( YK-   be the TR  = 
coeffic f , and  denote the 
 is added to the 
ient o de
d
termination for the r
1-k,d
egression of Yd  on K,dS 2kR
(population) increment in coefficient of determination when 
regression of Y  on S .  Then (9) becomes: 
 
 1-2
k,dS
KYP [ 1( 21)RKP-  - 21- )1( Rp 2) KK Rp-1- 21KP-  - …-  1( ]                               (10) 
oting that
 
n 2 TR  = multipli s the ‘variance inflation ∑ 2kR .  We refer t
 to the SMAR des
o the e
ign, which generalizes
r of 2Y  a
 to:    factor’ (VIF) due
 
       )1-( KPd - 211- ])1([ RPKKP-d  - 22        (11)                            
when randomization probabilities depend on prior state values.   
1-1-
1 ])1[( RPp KKP-d  - 1[( -d 21- ]) KK RPp K
 
 12 
http://biostats.bepress.com/cobra/art69
 Using either (10) or (11) as appropriate provides the SMAR version of the 
usual one-sample t-test formula for sample size: 
 
2
2/ )+(  zz 2
VIF
                                                                                 (12) 
ES
 
where   is the significance level, 1-   is the power to be achieved, and ES = 
Y-  )0( d  is the standardized difference between d and the null mean.   The 
rmul 2) assumes a two-sided test of the null hypothesis that a (1 dfo =  and 
te 
that th am
 of a 
rence for pairs of ATS, using pooled values for VIF and .  
owever, the pooled version of (12) does not address the possible role of 
s in a 
,0
k.  T
the (approximate) large sample normality of the semi-parametric estimator.  No
ple size calculation does not require any assumptions for the 
unknown distribution of the K,dS  when |( kk dp kS , 1-kA )  )( kk dp  f ll his 
would occur when subjects are allocated with equal probability to treatment 
alternatives, which themselves are equal in number at every decision point
particular stage.    
 
 The formula (12) extends in a straightforward way to sample size 
calculations for infe
e s
or a
2
Y
H
between-strategy covariance in causal inference.  Such covariance arise
SMAR trial because of the nested structure of the randomizations.  Dawson and 
Lavori (2010) use the regression quantities in (12) to provide an adjustment to 
SMAR sample size when covariance is substantial enough to increase efficiency.     
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4.  Semi-parametric Efficiency Gains with the Optimal Estimator 
 
Murphy (2005) obtains the simple MM estimator of d  and its standard error by 
setting each k in  to optU d .   To characterize the potential loss of efficiency in 
doing so, we express the variance of the MM estimator of d , denoted , in 
ANOVA form as: 
MMvˆ
              
MMvˆ vˆ ˆ ˆ =  + v                   v =  n ;b b 2)(
1 ˆ∑ 1- d -mPn KKK
Ks
                                    (13)   
                                                                                                                               
with accounting for response heterogeneity across subgroups indexed by state 
history (Lavori and Dawson 2007) .   
bvˆ
 
. We compare (13) to , as expressed in (6).  With some algebra, it 
follows from (7) that: 
OPTvˆ
   
])-( 2- ˆ[ˆ
1 1
kKk mPen
d  = 22 )(1 ˆ∑ 1-1- kKKkK -mnPPn
K

s
                         (14)                             
 
and 
 =  + +  OPTvˆ vˆn )(vˆ∑ KbK
K
P s
s
2
1
1=
)()1(
1 ∑∑ 1-
K
kKKkk
-K
k
--
n
mPp
s
                    (15) 
                                                 
where  is the summand of corresponding to )(vˆ Kb s bvˆ Ks .  Thus, the optimal 
variance estimator improves semi-parametric efficiency, in part, by 
downweighting .  bvˆ
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To further characterize efficiency gains, consider  and the term of (15) 
corresponding to k.  Define 
bvˆ
k  as: 
 
  k =   -                                                   (16) 2)( ˆ∑ d -KK m
Ks
2)( ˆ∑ kKK -m
K

s
 
which can be re-expressed as:   
 
              k =   =                                                                                                                  (17)22 ˆˆ∑ d -kk
ks
                                          
                      
noting that kˆ  = ∑ .  Suppose that  is binary (always 
achievable by introducing more stages), taking on values , .  Accordingly, 
1-
),,1+( KkK
m
Kk ss  kS
ks ks′
k  can be sequentially defined in terms of stage-specific response heterogeneity 
k  = k + 1-k  … + 2 + 1 ,   where  
- 
 k =  ;           2),(),( }{ ′ˆˆ′ 1-1-
1
1-∑ kkkkkkkkk ssff -
-k
ss
s
 1 = 1                                            (18) 
 
and = = 1-   1- .  The derivation follows by induction.     kf ′ ),( ′1- kkk sf s ),( 1- kkk sf s kf
                                                          
 We can re-express -  directly in terms of the OPTvˆ MMvˆ k when 
, )  for all k.  The case K = 3 suffices to concretely explicate 
the general result: 
|( kk dp kS 1-kA )( kk dp
. 
 =  + - OPTvˆ nvˆ bvp ˆ3 1213 )1( ppp - - 223 )1( pp -                                                               (19a) 
 
                   =  -  - MMvˆ bv-p ˆ)1( 3 1213 )1( ppp -  - 223 )1( pp -                                                  (19b)                                         
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The SMAR randomization probabilities, which are specified a priori by the trialist, 
govern increased semi-parametric efficiency provided by the optimal estimator, 
and do so in a simple way under the assumed restrictions.  The strength of the 
relationship of state history to Y, as evidenced by the magnitudes of the k , has 
impact as well, with  =  when there is no between-subgroup response 
heterogeneity at any stage of the stud y.   
OPTvˆ MMvˆ
 
 Simple differentiation of (19) shows that efficiency gains for the assumed 
SMAR set up are maximized (as a function of state history) when each  acts 
like a flip of a fair coin, thereby allowing sequential allocation of subjects to each 
possible state history.  The worst improvement occurs when at each stage but 
the last,  is a degenerate binomial, i.e., all mass on one outcome.  This makes 
intuitive sense if you consider that this scenario isn’t adaptive until the last stage, 
and is formally equivalent to the cross-sectional K = 1 case. 
kS
kS
 
 
5.  Simulation Studies 
 
A central issue to the sample size formula (12) is how well the parametric re-
expression of , derived using the assumption of homogeneity of 
variance, adequately matches non-parametric inference carried out using the 
estimators in Section 2.  It may be that successive stratification leads to one or 
more random zeroes at intermediate stages of randomization, even if the nominal 
level of power is achieved (in the frequency sense).  As the sample size grows, 
the chance of this diminishes.  We conducted simulations to understand the 
degree to which good performance of the sample size formula across repeated 
samples protects the trialist from an unlucky SMAR realization.  Because (12) 
may also fail to protect against near sampling zeroes (and thereby interfere with 
constrained randomization), we calculated the test statistic twice, using ML and 
semi-parametric estimators. 
)(UoptV
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 The simulation set up is designed to explicate the relationship between 
‘repleteness’, defined as the lack of random zeroes at any intermediate stage of 
the SMAR experiment, and calculated  sample size.  Data for the example ATS, 
described in the Introduction and denoted here as d, are generated by the 
following scheme.  The state space at each stage is {1,2,3}, which corresponds 
to “low, medium, or high” symptoms; these values determine whether to 
adaptively continue, augment or switch medication, using the stage-specific 
treatments specified by  d.   As in the STAR*D antidepressant study, baseline 
state is obtained after an initial trial on the medication A.  The  values are set 
to be equiprobable.  The values for  are produced according to the transition 
matrix TM with rows (0.7, 0.2, 0.1), (0.5, 0.3, 0.2), (0.1,0.5,0.4), where  = 
Pr(j|i).  The matrix TM is consistent with “healthier” subjects having greater 
probability of better successive outcomes.  The final outcome is generated as a 
regression on state history, with normal error:   = , 
~N(0,
1S
e
2S ,d
ijTM
dY T2 +, dS
e 2e where ), 21(  = (1.2) and the intercept 0 = 0.5 is the coefficient for 
  1. 0S
 
The randomization probabilities for assignment to d depend on prior state 
values: subjects who are (well, in partial remission, ill) continue on d with 
probability (1, 1/3, 1/2).   The values for the randomization probabilities are also 
suitable for generally investigating semi-parametric efficiency gains with the 
optimal estimator, because the analytic derivation required , ) 
 for all k.  For purposes of inference for 
|( kk dp kS 1-kA
)( kk dp d  (generated to be 6.10), we 
set the standardized effect size in the formula (12) to be either 0.2 or 0.4.   The 
trialist might specify the larger ES value to insure adequate precision for 
individual ATS means when planning a pilot SMAR trial.  The inherent ‘cost’ in 
successfully implementing a whole treatment strategy makes it unlikely that the 
trialist would find effects smaller than 0.2 of practical relevance.   
 17 
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 We note that an alternative version of the simulation set up described 
above was used to evaluate (12) for pairwise comparisons, and more generally 
for sizing a SMAR trial with equal randomization probabilities, with particular 
attention to the role played by between-strategy covariance (Dawson and Lavori 
2010).  To explicitly allow for simulated causal effects due to the final treatment 
KA  (for a K-stage trial), that set up included a ‘final’ state , not necessarily 
measured during a real trial, which was part of state history used to generate .  
For our context, including   in the simulation substantially increases the 
chance of a non-replete SMAR experiment in a way that would not occur in 
practice.  Because we do not have interest here in the use of (12) for causal 
inference, there is no reason to disallow the ‘null’ effect of final treatment.   
1+,KSd
dY
3,dS
 
 
 6.  Results 
 
Table 1 summarizes 2000 replications for every combination of ES = 0.2, 0.4 and 
e = 0.5, 1, 2.  Scenarios also varied by whether the simulated trial used a ‘safe’ 
mechanism to guarantee positive sample sizes across state histories at both 
stages of the simulated trial (Lavori and Dawson 2007).  Specially, ‘safe’ implies 
that once the number of subjects for a particular state history falls below a certain 
value (set here to 6), further randomization stops and subjects with those states 
continue on d thereafter.  The ‘safe’ mechanism is intended to reflect the effects 
of good practice, in the sense that the trialist would ensure repleteness, either 
through design or by monitoring subject accrual during the trial.  For all 
scenarios, randomized assignment was sequentially constrained via blocking to 
insure whenever possible that observed and expected allocations agreed.   
Throughout, the nominal level of power to be achieved was set to 0.80, with the 
level of the test = 0.05.  The test statistic, defined as the difference of the 
estimated mean and the null value divided by the standard error, was compared 
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to 1.96, suggested by asymptotic normality of the ML and semi-parametric 
estimators of d  . 
 
 The results show that when ES = 0.2, the calculated sample sizes insure 
repleteness for all but a very small number of experiments.  By contrast, when 
ES = 0.40, the proportion of replete experiments among the 2000 replications 
ranges from 60% to 89%.  One could argue that for most SMAR trials, the 
primary interest will be to detect moderate-sized causal effects, thereby 
increasing the sample size beyond that provided by (12) when ES = 0.4.  
Nonetheless, the simulations serve to illustrate the relevance of repleteness to 
good planning of a SMAR experiment, beyond the usual sample size 
considerations. 
 
 A more striking result in Table 1 is the differences in power achieved by 
the ML and optimal semi-parametric estimators.  The ML estimators are mostly 
robust to even substantial failures of repleteness, because of their use of sample 
quantities in (1) and (4) based on allocated proportions.  In contrast, the semi-
parametric reliance on assignment probabilities precludes the optimal estimator 
from tuning to the sample at hand, which may not be able to attain intended 
allocation proportions, due to sequential stratification of the sample across 
stages.  This is true even with mostly replete repetitions, highlighting the 
influence of near sampling zeroes on achieved power with semi-parametric 
estimation.  It is not surprising that the optimal estimator may sometimes be 
underpowered when the simulated trials use the ‘safe’ option, given that certain a 
priori randomization probabilities may be set to zero.   It is interesting that ML 
estimation insures nominal power under the ‘safe’ option, albeit conservatively for 
some scenarios.  This property makes it a suitable choice for inference, prior to 
the execution of the trial, and any knowledge of the stochastic process underling 
intermediate states.  This ‘self-tuning’ property of ML estimation in the face of 
random and near sampling zeroes reminds us that the (asymptotically derived) 
ML variance estimator coincides with the finite sample one obtained from the 
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method of moments.  We note that for practical purposes, the ML and semi-
parametric estimators of d  and its standard error show mostly minor 
differences.  This is expected, as the discrepancies across subgroup of subjects, 
stratified by state history, would tend to average out because the discrepancies 
reflect random chance.   However, the test statistic is a ratio, and can be 
sensitive to even small changes to its divisor.  
 
 Table 2 shows that repleteness and near sampling zeroes have a 
moderate impact on the semi-parametric efficiency gains provided by the optimal 
estimator, which entails estimation of the k  in  using inverse weights.  In 
theory, such gains should not depend on n, and simulations with excessively 
large sample sizes show this to be the case.  In the designed simulations carried 
out with realistic values for n, the relative efficiency for any given value of 
optU
e depended on whether the sample size was geared to ES = 0.2 or ES = 0.4.  
Nonetheless, the results of the simulations confirm that the strength of the 
relationship of state history to , as evidenced by the dY 2TR  values, governs the 
magnitude of efficiency gains.   
 
 
6.  Discussion  
 
In this paper, we have shown by asymptotic and algebraic proof that the ML and 
optimal semi-parametric estimators of d  and its standard error are equal under 
certain experimental conditions.  The two methodologies offer conceptually 
different formulations, which we exploit to develop a unified and efficient 
approach to design and inference for multi-stage SMAR trials with discrete 
intermediate states.  By applying a sequential version of the homogeneity of 
variance assumption often used for power calculations, we derived a sample size 
formula expressed in terms of a parametric (regression-based) version of the 
optimal semi-parametric population variance.  Our simulation studies show that 
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for finite samples, non-parametric (sample-based) ML estimation achieves 
nominal power across repeated experiments when randomization is sequentially 
constrained, even if some of those repetitions are not replete or suffer from near 
sampling zeroes.  In this sense, ML estimation offers ‘frequentist-based’ 
protection against near population zeroes, which the semi-parametric does not 
provide.  Moreover, it offers protection for the sample at hand, by providing at 
least nominal power when the trial design includes a ‘safe’ mechanism that 
selectively shuts down randomization when the number of subjects at a decision 
point falls below some minimum.  This makes ML estimation a suitable a priori 
choice for inference.  We note that the advantage of using observed rather than 
expected allocation proportions, exemplified by the simulation results for 
achieved power, has been discussed for studies with non-randomized treatments 
or missing data in terms of bias and efficiency (Rosenbaum 1987, Rotnizky and 
Robins 1995).    
 
The sample and population formulations of semi-parametric variance 
developed in this paper elucidate the central role played by response 
heterogeneity in determining the magnitude of sequential uncertainty.  Section 4 
offers a non-parametric characterization of sample response heterogeneity in 
terms of stage-specific between-subgroup sum of squares, which captures the 
sequential effect of response heterogeneity on semi-parametric efficiency.  The 
increments in regression-based coefficients of determination defined in Section 3 
provide the parametric counterparts at the population level, and analogously 
describe the sequential effect of response heterogeneity (via incremental 
strength of regression) on sample size requirements.  Because even the optimal 
(or worst) strategy would not be uniformly successful (or not) across state history, 
both characterizations apply generally to ATS under evaluation. 
 
Less apparent is the dual role played by response heterogeneity in SMAR 
trials and accordingly in estimators developed for their data structure.  Not only 
does response heterogeneity govern sequential efficiency, but also the entire 
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premise of an adaptive treatment strategy rests with a strong relationship 
between outcome and state on which to base decisions.  Because the SMAR 
design mimics sequential decision making, the missingness intentionally created 
by sequential (nested) randomization is governed implicitly by variation in 
responses across states for any given strategy.  In the absence of such variation, 
treatment assignment at any given stage reduces to a flip of a fair coin, making 
sequential adjustment for state history, as in the G-computational formula, 
unnecessary.  For certain estimators, such as the ML and optimal semi-
parametric ones considered here, their adjustment for SMAR missingness to 
guarantee consistency also reaps the usual efficiency gains, as translated to the 
sequential context. 
 
The framework developed here for ATS evaluation is appropriate when 
decisions are based on categorical symptom-based states, such as the clinical 
milestones (e.g., remit or not) used in managing chronic relapsing disorders 
(Rush et al. 2004)  and rapidly fatal diseases (Thall et al. 2007).   Bembom and 
van der Laan (2008) proposed a semi-parametric approach for the case when 
decisions are formalized as threshold rules based on continuous data, as might 
be appropriate for managing HIV/AIDS, and indicate extension to the optimal 
version would follow from standard theory.  For semi-parametric estimation of 
survival distributions in two-stage induction-maintenance oncology trials, Wahed 
and Tsiatis (2004) derived the locally efficient influence function that capitalizes 
on the time to response to the induction therapy, as a continuous covariate.  To 
date, sample size formulae have not been developed for the locally optimal case 
of Wahed and Tsiatis or the threshold designs of Bembom and van der Laan. 
 
 The results in this paper emphasize the importance of running a ‘tight’ 
trial, using sequentially constrained randomization in combination with some 
version of an a priori designated ‘safe’ option.  The trialist should also consider 
whether the calculated sample size will sufficiently protect against sparse data, 
and whether a larger number of subjects might circumvent the need for a ‘safe’ 
 22 
http://biostats.bepress.com/cobra/art69
option, which effectively truncates the ATS under evaluation.  The simulation set 
up provides one means to translate clinical judgments about intermediate 
response rates into the frequentist probability of experimental repleteness.  The 
trialist can also use the simulation set up to ‘firm up’ guesses for variance 
inflation factors when plausible values for regression quantities are lacking. 
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Appendix 
 
Proof of equality of optimal semi-parametric and ML variance estimators 
 
 
Claim 1:  Let kK |  = .  Then 1-kK
 
])-( 2- ˆ[ˆ
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Proof: 
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
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where kˆ  )(ˆ kk s  and the first k values of Ks (implied argument to K and Km ) 
are fixed at .  It follows from (7) and (A.1) that ks
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using the ANOVA decomposition (6). 
laim 2:   =  
 
 
C OPTvˆ MLvˆ  
 
Fix KK ss ′, , and (suppressing dependence on KK ss ′,  whenever possible) define 
stage-specific terms for MLvˆ and OPTvˆ , respectively:   
 
kG  =                                                 (A.8)  
 =                                         (A.9) 
a  kth-stage term  of 
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all equality of two variance estimators.  
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Table 1: Performance of Sample Size Formula for Nominal Power = 0.80 Using 
Either ML Estimation or Optimal Semi-parametric (SP) Estimation 
 
 
2
e   ES  Safe      VIF†      n‡   % Replete     Power:  ML   Power: Optimal SP 
______________________________________________________________________________________________________________________ 
                                                                         
                        
0.5     0.2    no       1.62     320      99.3%           0.798            0.737 
                   yes      1.62    320       100%           0.798            0.756  
          0.4    no       1.62       80      59.6%           0.818            0.664 
                   yes      1.62      80       100%            0.817            0.775   
 
1.0     0.2    no        2.05     404      99.9%          0.803            0.768 
                   yes      2.05      404      100%           0.801            0.766  
          0.4    no        2.05      101     72.2%           0.800            0.734 
                   yes       2.05     101       100%           0.849           0.826   
 
 2.0     0.2   no        2.97      587      100%            0.801            0.795 
                   yes      2.97      587       100%           0.792            0.784  
          0.4    no        2.97      147       88.6%          0.803            0.780 
                   yes       2.97     147       100%            0.846            0.847   
 
 
† Calculated from regression of  on  dY 2,dS
 
‡Calculated using formula (12)        
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Table 2: Relative Efficiency of Optimal Semi-parametric Estimator to MM Semi-
parametric Estimator 
 
 
 
2
e   ES  Safe      2TR †      n‡   % Replete       /  OPTvˆ MMvˆ
______________________________________________________________________________________________________________________ 
                                                                         
                        
0.5     0.2    no       0.95     320      99.3%           0.425             
                   yes      0.95     320      100%            0.434              
          0.4    no        0.95       80      59.6%           0.404             
                   yes       0.95      80       100%           0.626               
 
1.0     0.2    no         0.81     404      99.9%           0.508             
                   yes       0.81      404      100%           0.511              
          0.4    no         0.81      101     72.2%           0.460             
                   yes       0.81      101       100%          0.600               
 
 2.0     0.2   no        0.52      587      100%            0.687             
                   yes       0.52      587      100%           0.682              
          0.4    no         0.52     147       88.6%          0.607             
                   yes       0.52     147       100%           0.678       
 
† Calculated using expression (11) 
 
‡Calculated using formula (12)        
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